Bank of America Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target raised by equities research analysts at Bank of America from $13.00 to $15.00 in a report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Bank of America‘s price objective would indicate a potential upside of 66.30% from the stock’s current price.

A number of other analysts have also recently commented on the stock. Cantor Fitzgerald assumed coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, April 29th. They set an “overweight” rating and a $20.00 target price on the stock. Wall Street Zen cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 28th. Barclays upped their price objective on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 7th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $13.00 target price on shares of BioCryst Pharmaceuticals in a research note on Monday. Finally, Needham & Company LLC reissued a “buy” rating and issued a $17.00 price target on shares of BioCryst Pharmaceuticals in a research report on Wednesday, June 25th. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $16.70.

BioCryst Pharmaceuticals Stock Performance

BioCryst Pharmaceuticals stock opened at $9.02 on Tuesday. BioCryst Pharmaceuticals has a fifty-two week low of $6.02 and a fifty-two week high of $11.31. The stock’s 50 day simple moving average is $10.03 and its two-hundred day simple moving average is $8.58. The stock has a market cap of $1.89 billion, a price-to-earnings ratio of -34.69, a PEG ratio of 2.68 and a beta of 1.04.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in BCRX. Headlands Technologies LLC purchased a new stake in BioCryst Pharmaceuticals during the 1st quarter valued at $32,000. GF Fund Management CO. LTD. bought a new position in shares of BioCryst Pharmaceuticals during the fourth quarter valued at $33,000. GAMMA Investing LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 1,161.8% during the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 5,449 shares in the last quarter. New Age Alpha Advisors LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the first quarter valued at $62,000. Finally, Allspring Global Investments Holdings LLC bought a new stake in BioCryst Pharmaceuticals in the 1st quarter worth about $79,000. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.